Startup profile · funding coverage
IntelliProve funding, valuation and investors
Computer-vision-based physiological estimates from ordinary cameras for digital health platforms.
Verified company research · funding, investors and latest developments
Keep track of IntelliProve
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Seed
€2.7M · November 19, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
seed · Ghent, Belgium
Investors in latest funding
Lead: Miles Ahead
Other: Wit-Gele Kruis , imec.istart
Overview
Ghent company founded in 2021. Provides remote-photoplethysmography (rPPG) face-scan SDK and web components for camera-based heart rate, heart-rate variability, respiratory rate, estimated blood pressure and related wellness measures. November 19, 2026 press reports describe a €2.7M Seed led by Miles Ahead with Wit-Gele Kruis, imec.istart and angels participating, with exact closing date and valuation undisclosed.
Its own January 20, 2025 release documented a separate €1.25M investment. Developer docs specify roughly 20 seconds scanning while recent press descriptions say 30 seconds. Software-integration workflow: issue session token, request camera access, verify lighting and head positioning, run face scan, present biomarker widgets and escalate clinically important readings for conventional verification. Enterprise pricing is quote-based.
Do not interpret vendor-reported adoption in 50+ countries or an intended robotics use case as medical approval or evidence of diagnostic accuracy. Earlier 2025 company marketing describes CE status while a 2026 company job listing refers to a device still heading for CE marking; exact device/version and indication need verification.
Why IntelliProve is interesting
A reported €2.7M Seed led by Miles Ahead funds clinical validation and potential robotics integrations. The critical question is blood-pressure and heart-rate measurement reliability outside controlled settings, not the fundraising itself.
Product & use cases
B2B SDK rather than a dedicated physical scanner. Illustrative first visit: clinician/wellbeing platform obtains API token, embeds ip-session and face-scan widget, user grants camera, quality checks light/position, software returns physiological estimates, app shows relevant metrics and retains human escalation for clinical concerns. Source: https://docs.intelliprove.com/product-docs/face-scan-plug-in. No independently validated error rates or list price were established.
- Remote-care platform adds a contactless screening interaction.
- Wellness application displays an indicative physiological snapshot from a camera.
- Robotics developer could test health sensing on a moving camera; not a confirmed deployed medical application.
Funding history (newest first)
Seed
2026-11-19 €2.7M- Miles Ahead (lead)
- Wit-Gele Kruis (participant)
- imec.istart (participant)
Source: Read source · eu-startups.com
Earlier financing (series undisclosed)
2025-01-20 €1.25MSource: Read source · intelliprove.com
Competitive landscape
Edge: No specialized sensor required, but device compatibility, lighting bias, clinical accuracy and regulatory scope must be independently tested.
-
Binah.ai direct
Camera-based vital-sign estimation SDK.
-
NuraLogix direct
Contactless optical health measurements.
-
Traditional blood-pressure cuff alternative
Validated direct measurement for clinical workflows.
-
Wearable PPG devices alternative
Continuous measurements using dedicated hardware.
Notable stories
- Technology availability is not the same as medically validated accuracy; recent robotics use is a plan.
- Current documentation shows 20-second face scan; recent funding reporting says 30 seconds.
Market / IPO context
Editorial / static context — not a live quote.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.